Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | MOTS-c | Humanin |
|---|---|---|
| Class | Mitochondrial-derived peptide | Mitochondrial-derived peptide |
| Research category | metabolism and longevity | neuroprotection and metabolism |
| Evidence level | Low | Low |
| Overall status | Not approved — preclinical | Not approved — preclinical |
| FDA | Not approved | Not approved |
| EMA | Not approved | Not approved |
| WADA | Prohibited — check current list | Check current list |
| Mechanism studied | MOTS-c → Folate–methionine pathway → AICAR / AMPK → Glucose uptake | Humanin → FPRL1 / gp130 receptor → STAT3 / anti-apoptotic → Cell survival |
| Molecular weight | 2,174.6 g/mol | 2,687.2 g/mol |
| Sizes in stock | 10mg, 40mg | Not currently listed |
Where the research overlaps
Both compounds are studied within Longevity & Cellular Health research. MOTS-c is classed as mitochondrial-derived peptide, while Humanin is mitochondrial-derived peptide. Evidence is rated low for MOTS-c and low for Humanin.
For a full write-up, read Mitochondrial Peptides: MOTS-c, Humanin and SS-31.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.